Study on Female Sexual Dysfunction in Type 2 Diabetic Chinese Women

Abstract Objective To investigate the female sexual dysfunction （FSD） in type 2 diabetes patients, by comparing the sexual function between type 2 diabetic women and non-diabetic women with Female Sexual Function Index （FSFI）. Methods 215 type 2 diabetic women and 107 age-matched non-diabetes women were enrolled with similar backgrounds. Their sexual functions were evaluated with FSFI. Metabolic parameters such as body mass index, blood lipid profile, hemoglobin AlC, plasma glucose were also collected. Results Total score of FSFI of the type 2 diabetic women were significantly lower than that of the non-diabetic controls （18.27±8.96 vs. 23.02±5.78, P=0.000）. Scores of the FSFI domains （desire, arousal, lubrication, orgasm, satisfaction, pain） of the type 2 diabetic group were also lower than those of the control group. According to the FSD criterion （FSFI〈25） available in China, the percentage of FSD in the type 2 diabetic group was significantly higher than that of the control group （79.2% vs. 55.0%, P〈0.001）. These trends seemed more prominent in pre-menopause subgroups. The logistic regression analysis indicated that age and diabetes were independent risk factors of FSD. Body Mass Index （BMI） also had influence in the diabetes group. Conclusion Findings from this study showed that there are more FDS in Chinese type 2 diabetic women than in their non-diabetic counterparts, especially in pre-menopause participants.

Female Sexual Dysfunction among Chinese Primiparous Women

Objective: To compare sexual function between primiparous women who underwent cesarean section (CS) and those who delivered vaginally. Methods: This cross-sectional study was conducted from October 2011 to April 2012 in Beijing, China. The target population included women aged 18 - 45 years who had given birth only once at least 6 months prior. The questionnaire was self-administered including female sexual function measured using the Female Sexual Function Index (FSFI). Data were analyzed using R software with the significance level of 0.05. Results: A total of 1456 participants were included and 102 women (7.0%) declined. The median age of the participants was 35 years. The median time interval after childbirth was 6 years. The median FSFI score was 26.9 and prevalence of female sexual dysfunction (FSD) was 34.2%. Both the FSFI scores and the proportions of individuals with sexual disorders were similar between women undergoing CS and those having vaginal delivery for both individual domains and the full scale. Conclusion: There were insignificant differences in female sexual function scores and FSD prevalence between women undergoing CS versus vaginal delivery.

The Use of Natural Products for the Treatment of Female Sexual Dysfunction: A Systematic Review of Randomized Clinical Trials

Female sexual dysfunction (FSD) affects 40% of the world’s females, most of which are disorders linked to desire or interest/excitement. Whilst all types of therapy that attempt to improve female sexual desire have long been established, the results are contradictory. Objective: To analyze all available evidence to validate the effectiveness of natural therapies in the treatment of FSD. Method: The study was registered at http://www.prospero.org (CRD42019127700). We searched the Institute for Scientific Information Web of Knowledge, MEDLINE, Pubmed, Scopus and Cochrane databases for all articles published in peer- reviewed journals in April 2019 (in any language). The PICOS standard is women with FSD;(intervention) of any type of Natural therapy;(outcome) primary outcome: frequency of changes, severity, and average mean scores on sexual symptoms measured with a validated instrument, secondary outcome: quality of life;(study design) and randomized clinical trial (RCT). Results: The literature search strategy identified 95 articles, 81 of which were excluded at the different search stages. Finally, we systematically reviewed 15 RCTs, 11 of which referred to primary FSD, and four of which analyzed women with drug-induced FSD (DFSD). Most of them analyzed hypoactive sexual desire disorder. Although differences related to placebo were found in most people, the majority of the studies are considered to be of poor quality and low external effectiveness. Conclusion: Although the quality of the evidence is not high, most natural product interventions appear to improve FSD, particularly hypoactive sexual desire disorders including those categorized as primary and drug-induced.

Female Sexual Dysfunction in Elfayoum Governorate

Introduction: female sexual dysfunction (FSD) is a complex and poorly understood condition that affects females of all ages. Female sexual dysfunction has been a cyclic rather than a linear process that emphasizes biologic, psychological, social, hormonal, and environmental factors. Female sexual dysfunction is a high prevalent disorder reaching up to 60% of females with reported higher levels in postmenopausal. Aim of the work: was to estimate prevalence of FSD and its related factors in Elfayoum city. Subject and Method: This study was a cross sectional descriptive study conducted in Elfayoum city included 508 married females (above 21 years old) during the period from September 2016 to March 2017. Results: The prevalence of FSD among studied group was 61.2% versus 38.8% had normal sexual function, desire dysfunction was 42.3%, arousal dysfunction was 39.2%, lubrication dysfunction was 25%, orgasm dysfunction was 58.5%, satisfaction dysfunction was 58.1% and pain was 43.3%. There was statistically significant negative correlation between Female Sexual Function Index (FSFI) score and each of female and husband age, duration of marriage, and number of children. Low mean of FSFI score was found among females with irregular menstrual cycle, using contraceptive, not pregnant, mutilated and females who’s their husband had erectile or ejaculation disorders. Conclusion and recommendation: High prevalence of FSD among females in Elfayoum governorate. Many factors are found to affect FSD as FGM, each of female and husband age, duration of marriage, and number of children.

Assessment of Female Sexual Dysfunction in Patients with Premenopausal Female Pattern Hair Loss

Introduction: Female sexual dysfunction (FSD) is a serious problem that affects negatively the quality of life, interpersonal relationships and female self- confidence and might be a direct cause of psychopathological disturbances. Female pattern hair loss (FPHL) is a common cosmetically disturbing condition affecting many women with social and psychological consequences. Aim of the Work: Assessment of the relationship between female sexual dysfunction and Female pattern hair loss in premenopausal females. Methods: A case-control study was carried on 47 female patients with FPHL and 43 age- matched control women without FPHL among premenopausal women attending dermatology and Andrology outpatient’s clinics, Suez Canal University hospital during the period from May 2018 to January 2019. History taking, clinical examination and hormonal investigation (Free Testosterone, Total Testosterone, and SHBG) were performed to all participants in the study. Main Outcome Measures: The Female Sexual Function Index (FSFI) was used to assess the key aspects of female sexual function in patients and controls. FPHL was diagnosed and graded by Ludwig’s classification. Results: Mean age of patients group was 30.12 ± 5.49 years, Regarding FPHL grading, 55.3%, 42.6% & 2.1% of patients were grades 1, 2 and 3 Ludwig’s classification respectively. FSD was found in 44.7% of patients while it was 44.2% in control group (P > 0.05). FSFI score in patients group was 26.40 ± 4.61 and in control group was 27.05 ± 3.12 (P > 0.05). Correlation between FSD prevalence and grade of FPHL by Ludwig’s classification was statistically insignificant. FSD was significantly compromised by increasing age and parity in patients and control groups (P < 0.05). Conclusions: The present study suggests that FSD was not significantly related to FPHL. Increased age and parity may have strong impact on sexual function in premenopausal women, while androgen hormones levels were not determinant factor.

Therapeutic Approach in Female Sexual Dysfunctions in an Outpatient Clinic of Sexology in the Public Health System: A Longitudinal and Prospective Study

INTRODUCTION: Sexuality is one of the parameters of quality of life, and it is essential to include care for sexual dysfunctions in primary health care. OBJECTIVE: To evaluate the therapeutic approach in female sexual dysfunction in a public health outpatient clinic. DESIGN: A prospective cohort of women with sexual dysfunctions in an outpatient clinic of sexology in the Public Health System. The Female Sexual Function Index (FSFI) and scored 0 - 10 their sexual satisfaction were applied at the beginning and end of the follow-up. RESULTS: Eighty-nine women were included with a median age of 45 years, 69 (77.5%) had less than 11 years of schooling and 95.5% lived with a partner. The main reasons for referral for follow-up at the outpatient clinic of sexuality were dysfunction of hypoactive sexual desire disorder in 67.4% and pain related to sexual function in 46%. The average number of consultations was five and the main therapeutic interventions were guidance and clarification on sexuality (86.5%), use of topical estrogen (56.2%), and relaxation techniques (37.1%). All FSFI-19 domains had better post-intervention rates (p ≤ 0.005). Considering the domains of the FSFI-19, the medians of desire, arousal, lubrication, orgasm, pleasure and pain were higher in the post-intervention period in relation to the pre-intervention period (p ≤ 0.0001 for all analysis). In addition, the score given by the participant on their sexual satisfaction was higher at the post-intervention time compared to the pre-intervention period (p ≤ 0.0001). CONCLUSION: In public health, even with the care being performed by different professionals in each consultation, we conclude that through simple interventions, it is possible to improve the sexualities of the women attended. Still, offering care in sexuality is fundamental as part of primary health care and the training of medical professionals.

Sexual Dysfunction among Chinese Nurses:Prevalence and Predictors

This study aimed to estimate the prevalence of and identify the factors influencing female sexual dysfunction （FSD） among Chinese nurses. A cross-sectional survey was conducted from March 2013 to May 2014 among 6 hospitals in Suzhou, China. In total, 2,030 married female nurses were included in the analysis.

Sexual Satisfaction Is Reduced in the Female Patient and Sexually Intimate Partners Following Cancer Therapy

As cancer survival has continued to improve, cancer patients and their sexually intimate partner (SIP) are confronted with a number of issues including sexual function and overall sexual health. Our study objective was to assess changes in sexual function in women undergoing cancer treatment and their SIP, and attempt to identify areas of needed support and improvement. In this questionnaire-based observational study, females (n = 11) completed a Female Sexual Function Index (FSFI) and for SIP’s (n = 11), a Brief Sexual Function Inventory (BSFI). Level of satisfaction prior to and within 3 months following treatment with surgery, chemotherapy and/or radiation was compared. Mean pre-and post-treatment total (30.7 ± 2.7 vs. 23.2 ± 3.7, p < 0.001) and individual FSFI domains were significantly different for desire (4.2 ± 0.6 vs. 2.6 ± 0.6, p < 0.001), arousal (4.9 ± 0.4 vs. 3.5 ± 0.7, p = 0.001), lubrication (5.5 ± 0.4 vs. 4.5 ± 0.8, p = 0.006), orgasm (5.0 ± 0.6 vs. 3.8 ± 0.7, p = 0.001), satisfaction (5.3 ± 0.6 vs. 3.5 ± 0.9, p < 0.001), though no differences were noted with dyspareunia. For SIP’s, BSFI domain scores for level of satisfaction were significantly lower following partner treatment of SIPs (3.5 ± 5.2 vs. 2.5 ± 5.2, p = 0.004). Overall, female sexual dysfunction was identified in 9% of patients prior to cancer treatment and 91% (n = 11, p < 0.001) following treatment. In conclusion, cancer treatment significantly affects sexual function in female cancer patients and their SIPs. While long term effects on sexual dysfunction are still unclear, short-term health care strategies including treatment, counseling, and appropriate referral for cancer patients and their SIPs should not be overlooked.

Female Sexual Function after Surgical Treatment of Urinary Incontinence

Introduction: Urinary incontinence is a common problem that can affect the quality of life of women of all ages and can negatively influence the exercise of sexuality. Aim: The aim of this study was to compare sexual function of women before and after surgical treatment for urinary incontinence. Method: The sample consisted of 38 women with urinary incontinence and surgical treatment (Burch or Sling procedure). The Female Sexual Function Index (FSFI) was used to evaluate sexual dysfunction before and after surgical treatment. Results: The mean age of the women in the study was 48 ± 8.8 years, and 58% were 50 years old or younger. By analyzing FSFI, it was observed that the majority of subjects had an overall index of sexual dysfunction (score < 26 points) before surgery. The desire and arousal domains improved significantly after surgery for all women included in the study. It was also observed that women with higher levels of education had more positive results related to desire. Conclusions: In our sample, in general, sexual function improved after surgical treatment of urinary incontinence, regardless of technique used, particularly in the discounter and pain domain. There was a substantial improvement of the sexual function among women who had presented with cystocele. Desire and arousal improved significantly after surgery, very likely due to the improvement of self-esteem after surgery.

Sexual dysfunctions and their treatment in liver diseases

Sexual dysfunction(SD)is a prevalent but very commonly ignored aspect in the treatment of liver diseases and cirrhosis.The etiology of SD is multifactorial and therefore treatment strategies are complex,especially in females.Phosphodiesterase inhibitors are useful and effective in erectile dysfunction in males but in females,no single drug is available for SD,therefore multimodal treatment is required depending upon the cause.The foremost and fundamental requirement in both genders is to be stress-free and have adequate control of liver diseases.Improved quality of life is helpful in improving SD and vice versa is also true.Therefore,patients suffering from liver diseases should come forward and ask for treatment for SD,and physicians should actively enquire about SD while history taking and evaluating these patients.SD results in deterioration of quality of life,and both are modifiable and treatable aspects of liver diseases,which are never addressed actively,due to social taboos and fears of SD treatment in the presence of liver diseases.The diagnosis of SD does not require costly investigations,as the diagnosis can be established based on validated questionnaires available for both genders,therefore detailed targeted history taking using questionnaires is essential.Data are emerging in this area but is still at an early stage.More studies should be dedicated to SD in liver diseases.

Relationship between Female Sexual Function and Depression or Anxiety in Japan

Background: Sexual dysfunction is sexual complaints or disorders. There are various causes, but the onset leads to deterioration of relationships and quality of life with partners. There is still a deep-rooted awareness that sexuality is a secret in Japan. Aim: This study aims to clarify the relationship between female sexual function and depression or anxiety. Method: Four hundred and fifty-eight Japanese healthy women who worked in four randomly selected medical institutions in Okinawa Prefecture in Japan from March to May 2012 were asked to agree to a consent form of their own free will and participate in self-reported questionnaires. For their evaluation, the Female Sexual Function Index (FSFI;Rosen et al. 2000, which includes the six domains of desire, arousal, lubrication, orgasm, pain, and satisfaction) and the Kessler Psychological Distress Scale (K6;Kessler, 2002, which includes the following six items: felt nervous, hopeless, restless or fidgety, worthless, depressed, and felt that everything was an effort) was used. Moreover, participants’ characteristics showed age, marriage, menopause, annual income, and drinking. In addition, JMP16.2 and R 4.2.0 was used to perform Pearson’s chi-square test, Fisher’s exact test, Mann-Whitney U test, Kruskal-Wallis test, Steel-Dwass test, Spearman’s Rank-Order Correlation, and Cronbach’s alpha. This study was approved by the university and the medical institutional review board (IRB). Results: 178 women were included in the final analysis, and the median (IQR, interquartile range) was 39 (32 - 48) years old, and the mean ± SD (standard deviation) was 40.2 ± 10.4 years old. The median (IQR) and mean ± SD of FSFI Total Score were 22.0 (9.3 - 26.6) and 19.2 ± 9.6. The median (IQR) and the mean ± SD of K6 Total Score were 3 (0 - 7) and 4.2 ± 4.5. 16% of all women with a K6 Total Score of 10 and more, and 5% of all women with a K6 Total Score of 13 and more considered a serious mental illness. There was no clear association between female sexual function and depression or anxiety in all health worker participants between FSFI Total Score and K6 Total Score by Spearman’s Rank-Order Correlation Coefficient (ρ). However, there was a moderate correlation between the K6 Total Score and the FSFI Total Score in health worker participants with a K6 Total Score of 11 or more (n =19, ρ = ?0.62, P = 0.005). Moreover, there was a weak correlation between them in both married and drinking women or married and non-menopausal women. In the Mann-Whitney U test where few participants had morbid depression, significant relationships were found in the association between a sexual function with high depression or anxiety, whereas the low group had a K6 cut-off value of 11. Conclusion: Female sexual morbidity for high depression or anxiety should be managed with interventions. Especially, the intervention for decreasing female sexual function in the K6 Total Score of 11 or more will be needed, and a randomized study is required for more evidence.

生物电反馈刺激联合心理护理治疗对产后女性性功能障碍的作用

目的探索生物电反馈刺激与心理护理联合治疗对产后女性性功能障碍(FSD)的改善效果。方法采用随机数字表法将118例产后FSD患者分为对照组(n=59)和观察组(n=59),对照组给予生物电反馈刺激,观察组给予生物电反馈刺激及改良式心理护理联合治疗,疗程12周。于治疗前、后第12周评定患者盆底肌力、膀胱生物学功能并评估患者的抑郁(9条目患者健康问卷)、焦虑(7条目焦虑问卷)和性功能(女性性功能量表,FSFI)水平。结果观察组治疗后盆底肌力改善率优于对照组(P<0.05)。观察组与对照组膀胱初感充盈量与最大充盈量在治疗后均高于治疗前(P<0.05),且治疗后观察组的膀胱初感充盈量与最大充盈量高于对照组(P<0.05)。治疗结束后,观察组焦虑与抑郁评分低于对照组(P<0.05),而且观察组FSFI各项得分、总分均比对照组高(P<0.05)。结论生物电反馈刺激联合心理护理治疗能够有效提高初产妇FSD患者盆底功能、改善膀胱生物学功能,而且缓解了患者抑郁焦虑情绪、促进了性生活质量。

五倍可利洁娜霜用于女性性功能障碍(FSD)及性器官保健的研究

目的:探讨五倍可利洁娜霜对FSD中性交不适、性交疼痛的治疗及性器官保健方法。方法:对918例性交不适、性交疼痛患者采用五倍可利洁娜治疗,直接涂擦外阴皮肤、阴道口内外,一疗程(20天)后观察治疗结果,经统计处理后进行疗效分析。结果:性交不适、性交疼痛,一疗程痊愈率分别为:84.95%、78.54%;总有效率分别为:97.85%、95.75%。结论:五倍可利洁娜霜对FSD中的性交不适和性交疼痛有良好的治疗效果,特别是对因阴道干涩、性交疼痛难忍而长期终止性生活的情况,有助于性机能的恢复、重启。在应用中未发现任何毒副作用,不含激素类成份,可广泛用于FSD中相关病症的治疗,或用于围绝经期及有性活动人群的性器官保健。

Effective of Behavioral Treatment Combined with Psychological Counseling for Female Coital Disorder of Chinese

Objective: To explore the effects of the behavioral treatment combined with psychological counseling on female coital disorder in China. Methods: One hundred and sixteen female patients with coital disorder were divided into sexual behavior training combined with psychological counseling group (group A, 59 cases) and psychological counseling alone group (group B, 57 cases). Results: Forty-five cases cured (76.27%), eight eases improved (13.56%), and six cases invalid (10.17%), the general rate of effectiveness being 89.83% in group A while eleven cases cured (19.30%), twenty-one cases improved (36.84%), and twenty-five cases invalid (43.86%), the general rate of effectiveness being 56.14% in group B. The curative effect of group A was better than group B (P Conclusions: The behavioral treatment combined with psychological counseling is significantly effective in treating female coital disorder than psychological counseling alone and its long term follow-up results show that most of patients were satisfied with their sex life. However, the response of behavioral treatment of some patients who had bad experience on sexual things in the progress of their growing up or had long course of disease were not so good which deserves our special attention in the future study.

Sexual Function in Pregnant Women in the Public Health System

Introduction: Pregnancy is a unique situation and involves changes in sexuality. The aim is to evaluate sexual function and satisfaction in pregnant women under prenatal care provided by the public health system. Method: Cross-sectional study with pregnant women receiving ambulatory care in the public health system in the Southern region of Brazil conducted between November 2014 and September 2015. Results: 283 pregnant women were studied. The mean age was 27.7 ± 6.3 years;64% were white and 31.1% were nulliparous. In the total sample, 8.50% were in the first trimester of pregnancy, 37.4% were in the second trimester, and 54.1% were in the third trimester. The rate of global sexual dysfunction (score 26 points) was 55.5%, following the application of The Female Sexual Function Index (FSFI). Sexual dysfunction was significantly more prevalent in the third trimester (62%) compared to the first (33.3%) and second (50.9%) trimesters (p = 0.015). There was a significant difference in all domains, except in the desired domain, according to the trimester. Pregnant women in the third trimester showed significantly lower scores compared to those in the first trimester in the domains with significance. Conclusion: The prevalence of sexual dysfunction among pregnant women in the public system was high. Knowing that more than 50% of the pregnant women presented sexual dysfunction, it is essential to approach sexuality during prenatal care involving the couple.

新型温控射频治疗阴道松弛相关女性性功能障碍探究

目的了解新型温控射频技术对于阴道松弛相关FSD的最佳治疗次数及具体治疗疗效,并采用主观及客观评估指标结合方式进行评估。方法2020年7月至2021年2月至北京大学深圳医院妇科门诊就诊的FSD患者并具有VRS症状者,予新型温控射频技术治疗3次及5次,比较患者治疗3次时与治疗5次时的检测结果,评估新型温控射频技术治疗阴道松弛相关的FSD的疗效,并探讨不同治疗次数的疗效对比,以及客观及主观评估方式结果改变。结果(1)治疗3次后FSFI量表得分平均为(26.59±3.92),治疗5次FSFI量表平均得分为(27.12±1.84),差异无统计学意义(P>0.05)。(2)治疗3次后阴道容指治疗有效性与治疗5次后阴道容指治疗有效性差异无统计学意义(P>0.05)。(3)治疗3次后阴道口闭合程度治疗有效性与治疗5次后阴道口闭合程度治疗有效性差异无统计学意义(P>0.05)。(4)治疗3次后与治疗5次后VLQ得分差具有统计学意义(P<0.05)。(5)治疗3次后盆底肌肌力提升治疗有效性与治疗5次后盆底肌肌力提升治疗有效性差异无统计学意义(P>0.05)。结论在客观评估指标中,新型温控射频治疗3次与治疗5次无明显疗效差异,而主观评估指标中,射频治疗5次优于治疗3次。在保证客观评估指标有效的情况下,可以适当减少治疗次数。

非手术治疗产后性功能障碍的研究进展

产后性功能障碍(postpartum sexual dysfunction,PSD)是女性发病率较高的疾病,病因复杂,治疗方法多样,包括心理治疗、药物治疗、行为治疗、物理康复治疗和手术治疗等,目前PSD主要治疗措施仍是非手术治疗。盆底科医生应对产后女性恢复性生活过程中遇到的问题给予专业指导;药物治疗可有效缓解阴道干燥和灼热感;电刺激和生物反馈均可减轻性交痛,且生物反馈比电刺激在提高性欲、增加阴道润滑度方面更有优势;磁刺激不仅能提升盆底肌力,对产后性交痛也有一定疗效;盆底肌筋膜痛手法治疗则需要与其他治疗方式联合应用;射频治疗多用于改善阴道松弛及干涩。综述PSD非手术治疗中的干预措施及其适应证并评价其治疗效果,为探寻PSD的最佳非手术治疗方法提供可靠临床依据。

围绝经期与绝经后女性雄激素浓度对情绪障碍及性功能障碍的影响

目的探讨围绝经期与绝经后女性雄激素浓度对情绪障碍及性功能障碍的影响。方法募集2022年1月至2022年12月于首都医科大学附属北京妇产医院内分泌科就诊的280例40~65岁女性,包括绝经前76例、围绝经期84例和绝经后120例,测量身高、体质量、血压、腰围、臀围等指标,进行包括情绪障碍和性功能障碍等绝经相关症状的问卷调查。将围绝经期及绝经后女性分为情绪障碍组及对照组,性功能障碍组及对照组,采用化学发光免疫法检测血清卵泡刺激素、黄体生成素、雌二醇、孕酮、催乳素浓度,采用液相色谱串联质谱法检测血清性激素结合球蛋白、总睾酮、游离睾酮、生物活性睾酮、脱氢表雄酮、硫酸脱氢表雄酮、雄烯二酮、双氢睾酮浓度。结果与绝经前相比,围绝经期与绝经后女性的血清游离睾酮、生物活性睾酮、雄烯二酮、脱氢表雄酮、硫酸脱氢表雄酮浓度显著降低(P<0.05),但这些激素浓度在围绝经期与绝经后女性中差异无统计学意义(P>0.05);与绝经前相比,围绝经期与绝经后女性血清总睾酮浓度稍降低,但差异无统计学意义(P>0.05);围绝经期与绝经后女性情绪障碍与血清总睾酮浓度降低有关(P<0.05),性功能障碍与血清硫酸脱氢表雄酮浓度降低有关(P<0.05)。结论围绝经期与绝经后女性多种雄激素浓度下降,情绪障碍与血清总睾酮浓度降低有关,性功能障碍与血清硫酸脱氢表雄酮浓度降低有关。

生物反馈电刺激治疗围绝经期女性性功能障碍及对盆底肌力影响

目的:分析生物反馈电刺激联合雌激素和Kegel训练法盆底肌肉康复训练治疗围绝经期女性性功能障碍(FSD)疗效及对盆底肌力的影响。方法:选择2020年5月-2022年5月本院妇产科就诊的围绝经期FSD患者80例,随机数据表法为两组各40例,对照组给予阴道内局部应用雌激素联合Kegel训练法盆底肌肉康复训练,观察组在对照组基础上联合应用生物反馈电刺激治疗,均连续治疗8周。对两组治疗前后女性性功能指数量表(FSFI)评分、焦虑自评量表(SAS)评分、抑郁自评量表(SDS)评分及盆底肌力分级进行评价和对比。结果:治疗后两组FSFI评分较治疗前升高,SAS评分和SDS评分均较治疗前下降(P<0.05),观察组治疗后FSFI评分(31.18±2.31分)及盆底肌力分级均高于对照组(23.34±5.08分),SAS评分(44.06±3.35分)和SDS评分(45.81±5.22分)均低于对照组(53.54±2.39分、57.10±3.61分)(均P<0.05)。结论:围绝经期FSD患者局部应用雌激素基础上联合应用生物反馈电刺激和Kegel训练法进行盆底肌肉康复,能够显著改善患者性功能和心理状态,提升盆底肌力水平。

D型人格与女性终末期肾病患者性功能障碍发生风险的关系

目的探究D型人格与女性终末期肾病患者性功能障碍(SD)发生风险的关系。方法选取2020年7月至2022年3月上海中医药大学附属曙光医院诊治的109例终末期肾病且行腹膜透析的女性患者作为研究对象。根据D型人格量表(DS14)评分分为D型人格组(n=63)与非D型人格组(n=46)。比较两组的女性性功能指数(FSFI)总分及各维度评分,并采用Pearson分析D型人格与女性终末期肾病患者FSFI评分的关系,同时对女性终末期肾病患者发生SD进行单因素及多因素分析。结果D型人格组FSFI总分及各维度评分均低于非D型人格组,差异具有统计学意义(P<0.05);Pearson分析结果显示,DS14评分与性欲、性唤起、性高潮、阴道湿润、性满意度及性交痛等各维度评分及FSFI总分均呈负相关关系(P<0.05);终末期肾病患者SD发病率为73.39%(80/109),单因素分析结果显示,不同C反应蛋白(CRP)、甘油三酯(TG)、肌酐(Cr)、血尿素氮(BUN)、甲状旁腺激素(PTH)、血红蛋白(Hb)、白蛋白(ALB)的研究对象的SD发生情况比较,差异具有统计学意义(P<0.05);多因素分析结果显示,高表达CRP、TG、Cr、BUN、PTH及DS14低评分是女性终末期肾病患者发生SD的独立危险因素。结论D型人格可能在一定程度上提高女性终末期肾病患者发生SD的风险,因此对于这种人格特征的患者,应提前拟定对应干预方案,以预防SD的发生或改善SD状态。